Triple-positive breast cancer involves tumors positive for estrogen, progesterone, and HER2 receptors, affecting treatment decisions and strategies. Diagnosis includes imaging and biopsy to confirm ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA study evaluating ...
HER2-positive breast cancer, once associated with poor outcomes, now sees improved prognosis due to targeted therapies like Herceptin. Combination therapies and neoadjuvant treatments have enhanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results